Trials / Recruiting
RecruitingNCT07101601
Study of DM5167 in Patients With Advanced Solid Tumors
An Open-label, Dose-finding, Phase 1 Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile, and to Explore the Pharmacodynamic Profile of DM5167 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 58 (estimated)
- Sponsor
- DIGMBIO · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety. The aim of the study is to assess the safety and tolerability of DM5167 in patients with advanced solid tumors not respond to other treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DM5167 | Once daily for 28 days |
Timeline
- Start date
- 2024-10-24
- Primary completion
- 2026-10-30
- Completion
- 2027-01-31
- First posted
- 2025-08-03
- Last updated
- 2025-08-03
Locations
4 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07101601. Inclusion in this directory is not an endorsement.